Dodie Deming, NP
Acute Care · Loveland, CONPI 1275179228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Lilly USA, LLC at 29.2% of the total.
Across 72 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$432
- Novo Nordisk$265
- BETA Bionics, Inc.$228
- Abbott$175
- Dexcom, Inc.$154
- Boehringer Ingelheim$111
- plus $112 from 3 others
What the payments were for
- Food & beverage$1,39194%
- Education$433%
- Gifts$433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $432 |
| Novo Nordisk | 23 | $265 |
| BETA Bionics, Inc. | 5 | $228 |
| Abbott | 4 | $175 |
| Dexcom, Inc. | 3 | $154 |
| Boehringer Ingelheim | 6 | $111 |
| Mannkind Corporation | 2 | $85 |
| Insulet Corporation | 1 | $17 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,476 in reported general payments places this provider in the 80th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 393 | $631,745 |
| JardianceEmpagliflozin | 134 | $186,752 |
| OzempicSemaglutide | 119 | $155,476 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $145,028 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $61,642 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $57,675 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $51,448 |
| TrulicityDulaglutide | 27 | $44,408 |
| RybelsusSemaglutide | 26 | $29,719 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $27,634 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 14 | $22,471 |
| FarxigaDapagliflozin Propanediol | 18 | $22,199 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $18,136 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $8,446 |
| NovologInsulin Aspart | 16 | $6,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin N | $432 | $677,535440 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $111 | $248,393173 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $265 | $191,208161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 239 acute care providers in Colorado.
Other acute care in Loveland
- Sarah RoarkLoveland$2K
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
- Rachele RobertsAurora$19K
- Shari Nieman CorsoLittleton$14K
- Lauren SpitzingerDenver$13K
- Gregory CharlestonPueblo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.